NASDAQ NMS - GLOBAL MARKET · BIIB

+2.76% · +$5.29 · Vol 2.1M

Market closed · last close 4:00 PM ET · price as of 16:11:04 ET

Biogen Inc

Biotechnology

$197.24

+ Add to watchlist

Card

Relationship Map

Veridion Score

Refresh

Score snapshot refresh in progress

Veridion Score History · 90D

Composite trend over time

HISTORY REFRESH IN PROGRESS

HISTORY WINDOW BUILDING

AI Analysis

Sovereign

Why is BIIB moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.

Catalyst calendar

What can move BIIB next.

Earnings, ratings, disclosures, volume, and score-history events. Every row needs a dated receipt.

Congress / Score

Upcoming

No dated upcoming catalyst is present in the current source window.

Recent

Jul 15
Score
Score moved +17
56/NEUTRAL -> 73/BUY BIAS
Veridion score historySource
Jul 7
CongressSovereign
Hon. Maria Elvira Salazar sale disclosed
Disclosure detail is available inside Sovereign and Reserve.
STOCK Act filingUnlock receipt
Jul 7
CongressSovereign
Maria Elvira Salazar sale disclosed
Disclosure detail is available inside Sovereign and Reserve.
STOCK Act filingUnlock receipt
Jul 7
CongressSovereign
Maria Elvira Salazar sale disclosed
Disclosure detail is available inside Sovereign and Reserve.
STOCK Act filingUnlock receipt
Jul 2
CongressSovereign
Hon. Gilbert Cisneros sale disclosed
Disclosure detail is available inside Sovereign and Reserve.
STOCK Act filingUnlock receipt
Jul 2
CongressSovereign
Gilbert Cisneros purchase disclosed
Disclosure detail is available inside Sovereign and Reserve.
STOCK Act filingUnlock receipt
Jun 9
CongressSovereign
Ro Khanna sale disclosed
Disclosure detail is available inside Sovereign and Reserve.
STOCK Act filingUnlock receipt
Jun 9
CongressSovereign
Ro Khanna purchase disclosed
Disclosure detail is available inside Sovereign and Reserve.
STOCK Act filingUnlock receipt
Jun 8
CongressSovereign
Maria Elvira Salazar purchase disclosed
Disclosure detail is available inside Sovereign and Reserve.
STOCK Act filingUnlock receipt

Catalyst calendar

Dated receipts for BIIB are being assembled.

About Biogen Inc

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Listed since

1991

Employees

Country

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Company website →

Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open

$191.21

Day high

$198.58

Day low

$186.03

Previous close

$191.95

52W high

$205.06

-3.81% from high

52W low

$186.03

59% of range

Market cap

$28.3B

P/E

17.47×

EPS

$11.29

Shares out

147.6M

Volume

2.1M

VWAP

$195.37

Price history computed in-house

-0.96%

SMA 50 $198.31 · below

SMA 200 $198.31 · below

52W position 59%

Veridion warehouse edge

Warehouse intelligence for BIIB.

Veridion Score

0: 801: 532: 573: 544: 705: 70

Congress 30d

No recent disclosure on file.

Insider activity

See Form 4 panel below.

13F holders

None on file

Capital Web snapshots checked.

Disclosure-sourced lobbying and contract detail remains attributed in the full panels below.

Related public evidence

Relationship mapTrace receipt-backed holders and filings around BIIB.Congress disclosuresOpen receipt and filing context for BIIB.MethodologyReview score inputs, coverage rules, and limitations.

Data ledger

Quote and day range

Refresh interval: 30 seconds

Source: Market data

Veridion Score

Coverage building

Source: Veridion methodology

Chart and risk context

Daily bars with no missing-bar fill

Source: Market data

News and filings

Refresh intervals shown inside each panel

Source: Market news and federal filings

Financials

Statements refresh in progress

SEC Form 4 ledger

BIIB insider activity

Biogen Inc

Score

Coverage building

Pressure

Mixed

Filings

Buys / sells

0 / 0

Net value

Not disclosed

Insiders

Cluster

No multi-insider buying cluster in the last 90 days

Net pressure

Mixed: Not disclosed across loaded Form 4 rows.

Convergence not established

Loaded official disclosures do not show all three sources aligned on this ticker.

Coverage building

The current Form 4 feed did not return value-bearing open-market rows for BIIB.

Source: SEC EDGAR Form 4. Rows with missing price or quantity are excluded rather than zero-filled.Methodology

Congress · 90D

Congress filing snapshot refresh in progress

Federal contracts

BIIB contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed

Refresh interval: 12hSource: Federal contract awards

No federal contracts on file for BIIB in this window.

Lobbying spend

BIIB lobbying filings, year to date.

Registered lobbying filings matched to Biogen Inc.

$2.4M

Refresh interval: 12hSource: LDA disclosure filings

Health Issues Medical/Disease Research/Clinical Labs Taxation/Internal Revenue Code Trade (domestic/foreign) Pharmacy Copyright/Patent/TrademarkHealth Issues Medicare/MedicaidMedicare/Medicaid Health Issues Pharmacy Taxation/Internal Revenue Code Trade (domestic/foreign)

Filing

$1.5M

BIOGEN

Apr 20, 2026

Filing

$770.0K

BIOGEN

Jan 19, 2026

Filing

$60.0K

BIOGEN INC.

DLA PIPER LLP (US)